Estimating the relapse risk of Plasmodium vivax in Iran under national chemotherapy scheme using a novel method

Journal of Vector Borne Diseases

Volumn 43, Issue 4, 2006, Pages 168-172

  Haghdoost, Ali Akbar ^a   Mazhari, Shahrzad ^a   Bahaadini, Kambiz ^b,c  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c LIONS EYE INSTITUTE   (Australia)

Author keywords

Antimalaria treatment; Cox regression; Iran; Malaria; Relapse of Plasmodium vivax

Indexed keywords

CHLOROQUINE; PRIMAQUINE;

ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; HUMAN; INFECTION RISK; IRAN; MAJOR CLINICAL STUDY; MALARIA; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; RECURRENCE RISK;

ANIMALS; ANTIMALARIALS; HUMANS; IRAN; MALARIA, FALCIPARUM; MALARIA, VIVAX; PLASMODIUM VIVAX; PROPORTIONAL HAZARDS MODELS; RECURRENCE; SEASONS; TIME FACTORS;

EID: 33845452929     PISSN: 09729062     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Prasad RN, Virk KJ, Sharma VP. Relapse/reinfection patterns of Plasmodium vivax infection: a four year study. Southeast Asian J Trop Med Pub Hlth 1991; 22(4): 499-503.
2. Adak T, Sharma VP, Orlov VS. Studies on the Plasmodium vivax relapse pattern in Delhi, India. Am J Trop Med Hyg 1998; 59 (1): 175-9.
3. Craig AA, Kain KC. Molecular analysis of strains of Plasmodium vivax from paired primary and relapse infections. J Infect Dis 1996; 174(2): 373-9.
4. Khusmith S, Tharavanij S, Bunnag D. Antigenic disparity of Plasmodium vivax causing initial symptoms and causing relapse. Southeast Asian J Trop Med Pub Hlth 1998; 29(3): 519-24.
5. Kirchgatter K, Delportillo HA. Molecular analysis of Plasmodium vivax relapses using the MSP1 molecule as a genetic marker. J Infect Dis 1998, 177(2): 511-5.
6. Gogtay NJ, Desai S, Kadam VS, Kamtekar KD, Dalvi SS, Kshirsagar NA. Relapse pattern of Plasmodium vivax in Mumbai: a study of 283 cases of vivax malaria. J Assoc Phys India 2000; 48(11): 1085-6.
7. Leslie T, Rab MA, Ahmadzai H, Durrani N, Fayaz M, Kolaczinski J, Rowland M. Compliance with 14-day primaquine therapy for radical cure of vivax malaria - a randomized placebo-controlled trial comparing unsupervised with supervised treatment. Trans R Soc Trop Med Hyg 2004; 98(3): 168-73.
8. Rowland M, Durrani N. Randomized controlled trials of 5- and 14-days primaquine therapy against relapses of vivax malaria in an Afghan refugee settlement in Pakistan. Trans R Soc Trop Med Hyg 1999; 93(6): 641-3.
9. Manson J. Patterns of Plasmodium vivax recurrence in a high-incidence coastal area of El Salvador, C. A. Am J Trop Med Hyg 1975; 24(4): 581-5.
10. Haghdoost AA. Assessment of seasonal and climatic effects on the incidence and species composition of malaria by using GIS methods (Dissertation). London: London School of Hygiene and Tropical Medicine 2004: p. 85-97.
11. Richie TL. Interactions between malaria parasites infecting the same vertebrate host. Parasitol 1988; 96(pt 3): 607-39.
12. Bruce MC, Donnelly CA, Alpers MP, Galinski MR, Barnwell JW, Walliker D, Day KP. Cross-species interactions between malaria parasites in humans. Science 2000; 287(5454): 845-8.
13. Molineaux L, Storey J, Cohen JE, Thomas A. A longitudinal study of human malaria in the West Savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. Am J Trop Med Hyg 1980; 29(5): 725-37.